MedTrace Logo

Toripalimab With Chemotherapy for Sinus Cancer

NCT06940180 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-26

No results posted yet for this study

Summary

The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers.

The names of the study drugs used in this research study are:

* Toripalimab (a type of monoclonal antibody)
* Carboplatin (a type of antineoplastic agent)
* Docetaxel (a type of antineoplastic agent)
* Cisplatin (a type of antineoplastic agent)

Conditions

  • Sinonasal Cancer
  • Paranasal Sinus Neoplasms
  • Squamous Cell Carcinoma
  • Sinonasal Undifferentiated Carcinoma
  • Locally Advanced Head and Neck Cancer

Interventions

DRUG

Toripalimab

An anti-PD-1 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.

DRUG

Carboplatin

An antineoplastic agent, multi-dose vials, via intravenous (into the vein) infusion per standard of care.

DRUG

Docetaxel

A taxoid antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.

RADIATION

Radiation Therapy

per standard of care

DRUG

Cisplatin

An antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    collaborator INDUSTRY

  • Glenn J. Hanna

    lead OTHER

Principal Investigators

  • Glenn J Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-17
Primary Completion
2028-02-01
Completion
2029-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06940180 on ClinicalTrials.gov